Minerva Neurosciences Company Profile (NASDAQ:NERV)

About Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences logoMinerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $304.64 million
  • Outstanding Shares: 36,704,000
Average Prices:
  • 50 Day Moving Avg: $7.34
  • 200 Day Moving Avg: $9.94
  • 52 Week Range: $6.50 - $15.84
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.50
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.90 per share
  • Price / Book: 2.86
Profitability:
  • EBIDTA: ($32,900,000.00)
  • Return on Equity: -33.78%
  • Return on Assets: -25.83%
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 9.18%
  • Quick Ratio: 9.18%
Misc:
  • Average Volume: 161,522 shs.
  • Beta: 1.98
  • Short Ratio: 10.46
 

Frequently Asked Questions for Minerva Neurosciences (NASDAQ:NERV)

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences Inc (NASDAQ:NERV) issued its quarterly earnings results on Thursday, May, 4th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. View Minerva Neurosciences' Earnings History.

Where is Minerva Neurosciences' stock going? Where will Minerva Neurosciences' stock price be in 2017?

2 brokerages have issued 12-month price targets for Minerva Neurosciences' stock. Their predictions range from $17.00 to $17.00. On average, they anticipate Minerva Neurosciences' stock price to reach $17.00 in the next twelve months. View Analyst Ratings for Minerva Neurosciences.

What are analysts saying about Minerva Neurosciences stock?

Here are some recent quotes from research analysts about Minerva Neurosciences stock:

  • 1. According to Zacks Investment Research, "Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. " (5/16/2017)
  • 2. Jefferies Group LLC analysts commented, "We believe NERV's two candidates MIN-101 and -202 offer upside to shares. MIN-101, designed to treat negative symptoms in schizophrenia, an unmet need, has demonstrated stat sig benefits in PIIb. MIN-202, partnered with JNJ, may offer an effective tx to insomnia with fewer side effects, and has demonstrated positive data in PIIa with stat sig improvements in key sleep parameters. We assume with Buy and $17 PT." (3/6/2017)

Who are some of Minerva Neurosciences' key competitors?

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the folowing people:

  • Marc D. Beer, Independent Chairman of the Board
  • Remy Luthringer Ph.D., President, Chief Executive Officer, Director
  • Geoffrey Race, Executive Vice President and Chief Financial Officer
  • Joseph Reilly, Chief Operating Officer, Vice President
  • Frederick Ahlholm CPA, Chief Accounting Officer, Vice President
  • Mark Levine, Vice President, General Counsel, Secretary
  • Francesco de Rubertis Ph.D., Independent Director
  • David J. Kupfer M.D., Independent Director
  • Fouzia Laghrissi-Thode M.D., Independent Director
  • Michele Ollier M.D., Independent Director

Who owns Minerva Neurosciences stock?

Minerva Neurosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (14.12%), Vanguard Group Inc. (2.66%), Perceptive Advisors LLC (2.21%), Nexthera Capital LP (2.06%), MARSHALL WACE ASIA Ltd (1.22%) and Marshall Wace North America L.P. (1.22%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Marc D Beer, Mark S Levine, Remy Luthringer and Venture Associates L Index III. View Institutional Ownership Trends for Minerva Neurosciences.

Who sold Minerva Neurosciences stock? Who is selling Minerva Neurosciences stock?

Minerva Neurosciences' stock was sold by a variety of institutional investors in the last quarter, including Iguana Healthcare Management LLC, Morgan Stanley, JPMorgan Chase & Co., Credit Suisse AG, Goldman Sachs Group Inc., ProShare Advisors LLC, Alliancebernstein L.P. and SG Americas Securities LLC. Company insiders that have sold Minerva Neurosciences stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Mark S Levine, Remy Luthringer and Venture Associates L Index III. View Insider Buying and Selling for Minerva Neurosciences.

Who bought Minerva Neurosciences stock? Who is buying Minerva Neurosciences stock?

Minerva Neurosciences' stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., MARSHALL WACE ASIA Ltd, Nexthera Capital LP, PNC Financial Services Group Inc., Vanguard Group Inc., Renaissance Technologies LLC, Handelsbanken Fonder AB and Citadel Advisors LLC. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer and Marc D Beer. View Insider Buying and Selling for Minerva Neurosciences.

How do I buy Minerva Neurosciences stock?

Shares of Minerva Neurosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Minerva Neurosciences' stock price today?

One share of Minerva Neurosciences stock can currently be purchased for approximately $8.30.


MarketBeat Community Rating for Minerva Neurosciences (NASDAQ NERV)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Minerva Neurosciences (NASDAQ:NERV) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $17.00 (104.82% upside)

Analysts' Ratings History for Minerva Neurosciences (NASDAQ:NERV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/23/2017ValuEngineUpgradeSell -> HoldLowView Rating Details
3/6/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$17.00N/AView Rating Details
5/26/2016JMP SecuritiesBoost Price Target$10.00 -> $17.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Minerva Neurosciences (NASDAQ:NERV)
Earnings by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Earnings History by Quarter for Minerva Neurosciences (NASDAQ:NERV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.30)($0.30)ViewListenView Earnings Details
3/13/2017Q4 2016($0.25)($0.27)ViewN/AView Earnings Details
11/3/2016Q316($0.21)($0.24)ViewListenView Earnings Details
8/4/2016Q116($0.30)($0.18)ViewListenView Earnings Details
5/3/2016Q1($0.33)($0.29)ViewListenView Earnings Details
3/14/2016Q4($0.31)($0.34)ViewListenView Earnings Details
11/5/2015Q315($0.43)($0.24)ViewListenView Earnings Details
8/5/2015Q215($0.53)($0.27)ViewN/AView Earnings Details
3/26/2015Q414($0.53)($0.40)ViewN/AView Earnings Details
11/6/2014Q3 2014($2.30)($1.53)ViewN/AView Earnings Details
8/7/2014Q2($0.41)($2.33)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Minerva Neurosciences (NASDAQ:NERV)
2017 EPS Consensus Estimate: ($1.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.30)($0.30)($0.30)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.47)($0.47)($0.47)
Q4 20171($0.48)($0.48)($0.48)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Minerva Neurosciences (NASDAQ:NERV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Minerva Neurosciences (NASDAQ:NERV)
Insider Ownership Percentage: 28.10%
Institutional Ownership Percentage: 69.81%
Insider Trades by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Insider Trades by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/20/2017Marc D BeerDirectorBuy50,000$8.12$406,000.00View SEC Filing  
2/6/2017Geoff RaceCFOSell21,450$11.02$236,379.00View SEC Filing  
2/6/2017Remy LuthringerCEOSell34,281$11.02$377,776.62View SEC Filing  
1/11/2017Joseph H ReillyCOOSell1,600$12.03$19,248.00View SEC Filing  
1/4/2017Mark S LevineSVPSell17,500$12.00$210,000.00View SEC Filing  
12/27/2016Frederick W AhlholmSVPSell17,000$12.51$212,670.00View SEC Filing  
8/10/2016Venture Associates L Index IIIMajor ShareholderSell1,000,000$10.00$10,000,000.00View SEC Filing  
6/21/2016David KupferDirectorBuy55,635$10.84$603,083.40View SEC Filing  
3/17/2016David KupferDirectorBuy181,488$5.51$999,998.88View SEC Filing  
3/18/2015Care Capital Iii LlcMajor ShareholderSell1,206,700$5.75$6,938,525.00View SEC Filing  
3/18/2015Rubertis Francesco DeDirectorBuy202,634$4.81$974,669.54View SEC Filing  
3/13/2015& Johnson JohnsonMajor ShareholderBuy607,903$4.81$2,924,013.43View SEC Filing  
1/26/2015Care Capital Iii LlcMajor ShareholderSell482,112$5.11$2,463,592.32View SEC Filing  
1/8/2015Care Capital Iii LlcMajor ShareholderSell531,808$7.38$3,924,743.04View SEC Filing  
7/7/2014Care Capital Iii LlcMajor ShareholderBuy737,500$6.00$4,425,000.00View SEC Filing  
7/7/2014Michele OllierDirectorBuy1,620,833$6.00$9,724,998.00View SEC Filing  
7/1/2014Coelho Rogerio VivaldiCEOBuy41,667$6.00$250,002.00View SEC Filing  
7/1/2014Frederick W AhlholmCAOBuy10,000$6.00$60,000.00View SEC Filing  
7/1/2014Geoff RaceCFOBuy33,333$6.00$199,998.00View SEC Filing  
7/1/2014Heek G Jan VanDirectorBuy3,333$6.00$19,998.00View SEC Filing  
7/1/2014Joseph H ReillyInsiderBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Minerva Neurosciences (NASDAQ:NERV)
Latest Headlines for Minerva Neurosciences (NASDAQ:NERV)
Source:
DateHeadline
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - May 23 at 3:08 PM
seekingalpha.com logoA Deep Dive Into Minerva Neurosciences' Pipeline
seekingalpha.com - May 16 at 6:31 PM
reuters.com logoBRIEF-Minerva Neurosciences announces outcome of meeting with FDA
www.reuters.com - May 16 at 6:31 PM
zacks.com logoMinerva (NERV) Provides Phase III Development Strategy for MIN-101
www.zacks.com - May 16 at 6:31 PM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - May 16 at 7:34 AM
streetinsider.com logoMinerva Neurosciences (NERV) Reports Outcome of End-of-Phase 2 Meeting With FDA
www.streetinsider.com - May 15 at 6:08 PM
finance.yahoo.com logoMinerva Announces Outcome of End-of-Phase 2 Meeting With FDA
finance.yahoo.com - May 15 at 10:13 AM
finance.yahoo.com logoMinerva Provides Update on Phase 3 Design and Development Strategy for MIN-101
finance.yahoo.com - May 15 at 10:13 AM
finance.yahoo.com logoMinerva Neurosciences stock rises 7% on plans to advance schizophrenia drug to late-stage trials
finance.yahoo.com - May 15 at 10:13 AM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Releases Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - May 8 at 5:44 PM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 6 at 9:08 AM
reuters.com logoBRIEF-Minerva Neurosciences Q1 loss per share $0.30
www.reuters.com - May 4 at 6:53 PM
finance.yahoo.com logoInvestor Network: Minerva Neurosciences Inc to Host Earnings Call
finance.yahoo.com - May 4 at 11:25 AM
finance.yahoo.com logoMinerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates
finance.yahoo.com - May 4 at 11:25 AM
marketbeat.com logoMinerva Neurosciences reports 1Q loss
marketbeat.com - May 4 at 8:46 AM
americanbankingnews.com logoMinerva Neurosciences (NERV) Receives Daily News Sentiment Rating of 0.31
www.americanbankingnews.com - May 3 at 11:18 PM
americanbankingnews.com logo Brokerages Anticipate Minerva Neurosciences Inc (NERV) to Announce -$0.30 EPS
www.americanbankingnews.com - May 3 at 8:24 PM
americanbankingnews.com logoMinerva Neurosciences (NERV) Earns News Sentiment Rating of 0.31
www.americanbankingnews.com - April 29 at 1:19 AM
nasdaq.com logoMinerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4,
www.nasdaq.com - April 28 at 12:19 AM
finance.yahoo.com logoMinerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4, 2017
finance.yahoo.com - April 27 at 9:57 AM
americanbankingnews.com logoMinerva Neurosciences (NERV) Receiving Somewhat Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 24 at 9:03 PM
finance.yahoo.com logoLifeSci Capital Initiates Coverage of Minerva Neurosciences
finance.yahoo.com - April 18 at 6:10 PM
americanbankingnews.com logoMinerva Neurosciences (NERV) Earning Somewhat Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 15 at 2:55 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Minerva Neurosciences Inc (NERV) to Announce -$0.30 EPS
www.americanbankingnews.com - April 12 at 4:09 PM
bizjournals.com logoFormer Aegerion chief Marc Beer to launch new Boston biotech
www.bizjournals.com - April 7 at 11:26 AM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 5 at 9:52 PM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 5 at 9:01 AM
americanbankingnews.com logoZacks Investment Research Upgrades Minerva Neurosciences Inc (NERV) to "Hold"
www.americanbankingnews.com - March 30 at 11:24 PM
globenewswire.com logoMinerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market ... - GlobeNewswire (press release)
globenewswire.com - March 23 at 7:18 PM
streetinsider.com logoMinerva Neurosciences (NERV) Reports Exercise of Warrants, Purchase of Common Stock by Chairman
www.streetinsider.com - March 21 at 11:40 PM
nasdaq.com logoMinerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open
www.nasdaq.com - March 21 at 6:40 PM
finance.yahoo.com logoMinerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of Directors
finance.yahoo.com - March 21 at 6:40 PM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Director Buys $406,000.00 in Stock
www.americanbankingnews.com - March 21 at 1:25 PM
biz.yahoo.com logoMINERVA NEUROSCIENCES, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - March 21 at 11:34 AM
thestreet.com logoBiotech Premarket Movers: Esperion, Minerva and BioCryst
www.thestreet.com - March 21 at 11:34 AM
finance.yahoo.com logoMINERVA NEUROSCIENCES, INC. Financials
finance.yahoo.com - March 16 at 7:30 PM
finance.yahoo.com logoMinerva Neurosciences reports 4Q loss - Yahoo Finance
finance.yahoo.com - March 13 at 6:28 PM
biz.yahoo.com logoMINERVA NEUROSCIENCES, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 13 at 10:09 AM
biz.yahoo.com logoQ4 2016 Minerva Neurosciences Inc Earnings Release - Before Market Open
us.rd.yahoo.com - March 13 at 10:09 AM
us.rd.yahoo.com logoMinerva Neurosciences Reports Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates
us.rd.yahoo.com - March 13 at 10:09 AM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Set to Announce Earnings on Monday
www.americanbankingnews.com - March 11 at 12:43 AM
finance.yahoo.com logoMinerva Neurosciences to Report Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates on March 13, 2017
finance.yahoo.com - March 6 at 6:18 PM
thestreet.com logoBiotech Premarket Movers: PTC, Teligent, Minerva
www.thestreet.com - March 6 at 6:18 PM
finance.yahoo.com logoMinerva Neurosciences to Present at Cowen and Company 37th Annual Health Care Conference on March 7, 2017
finance.yahoo.com - February 28 at 10:23 AM
finance.yahoo.com logoMinerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia
finance.yahoo.com - February 21 at 6:07 PM
finance.yahoo.com logoXO1 Founding Management Team Re-Unite to Launch SuperX and Announce $11m Series A Funding With Medicxi and Johnson & Johnson Innovation-JJDC
finance.yahoo.com - February 9 at 5:45 AM
zacks.com logoMinerva Presents Additional Data from Schizophrenia Drug
www.zacks.com - January 23 at 9:54 AM
biz.yahoo.com logoMINERVA NEUROSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - January 6 at 7:29 PM
globenewswire.com logoMinerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer - GlobeNewswire (press release)
globenewswire.com - December 22 at 6:30 AM
us.rd.yahoo.com logo8:39 am Minerva Neurosciences appoints Michael Davidson, M.D., as chief medical officer effective December 19, 2016
us.rd.yahoo.com - December 20 at 12:44 PM

Social

Chart

Minerva Neurosciences (NERV) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff